PolyPid: Strong Phase 3 Data Support A Buy Ahead Of November's FDA Decision

Impact · against what's priced in

PolyPid remains a high-risk binary play ahead of the November 28 FDA decision. While the Phase 3 data and Azurity partnership provide a bullish framework, these elements are already well-known and integrated into the current valuation, leaving the upcoming regulatory decision as the only remaining significant catalyst.

PYPD+0.10

No priced-in read yet

In context

The stock is trading ahead of a November 28 FDA decision on D-PLEX100, with upside supported by SHIELD II data and a partnership with Azurity worth up to $320 million.

Read from the article alone

• healthcare
• biotech
• PYPD
• binary risk
• clinical trials
• fda
• fda decision
• israel
• phase 3
• surgical infections

Search tags